Lipocine Announces Deletion of Unauthorized Changes to Company's Website

Rhea-AI Summary

Lipocine Inc. (NASDAQ: LPCN) announced that an independent contractor made unauthorized statements on its website, falsely claiming that TLANDO was approved by the FDA. The company confirmed that TLANDO has not received final FDA approval. Upon discovering the erroneous posting, Lipocine promptly removed the incorrect information from its website to maintain accurate communication.

Positive

• None.

Negative

• Unauthorized statements on website could lead to regulatory scrutiny.
• Potential confusion among investors regarding TLANDO's FDA status.

SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent contractor posted on Lipocine's website (www.lipocine.com), without authorization from Lipocine, statements suggesting that TLANDO was approved by the U.S. Food and Drug Administration ("FDA"). TLANDO has not received final approval from the FDA. Upon learning of the unauthorized posting to its website, Lipocine deleted the incorrect posting.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-announces-deletion-of-unauthorized-changes-to-companys-website-301188971.html

SOURCE Lipocine Inc.

FAQ

What did Lipocine announce on December 8, 2020?

Lipocine announced the deletion of unauthorized statements on its website regarding TLANDO's FDA approval.

What is the stock symbol for Lipocine?

The stock symbol for Lipocine is LPCN.

Has TLANDO received FDA approval?

No, TLANDO has not received final approval from the FDA.

Why did Lipocine delete information from its website?

Lipocine deleted the information to correct unauthorized statements suggesting TLANDO was FDA approved.